SynthesisBMC infectious diseases2023
Comparison of presepsin and Mid-regional pro-adrenomedullin in the diagnosis of sepsis or septic shock: a systematic review and meta-analysis.
Synthesis in BMC infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Non-Infectious Causes for Elevated Procalcitonin.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Diagnostic efficacy of serum presepsin for postoperative infectious complications: a meta-analysis.Frontiers in immunology · 2023Pooled it
- Prognostic Role of Mid-Regional Proadrenomedullin in Patients Undergoing Emergency Laparotomy: An Exploratory Study.Cureus · 2026Article
- Assessment of intracellular complexity of monocyte through cell population data (CPD) can lead to early recognition of bloodstream infections.Archives of microbiology · 2026Observational
- Serial assessment of serum HMGB1 and ΔSOFA for predicting 28-day mortality in sepsis patients: a prospective cohort study in the emergency department.BMC emergency medicine · 2026Article
- Sepsis Biomarkers in Evolution: Comparative Insights and the Promising Roles of MDW and Presepsin.Medicina (Kaunas, Lithuania) · 2026Review
- From sepsis biomarker discovery to regulatedFrontiers in medical technology · 2026Review
- Early Use of Innovative Biomarkers Such as Mid-Regional Pro-Adrenomedullin and SeptiCyteInternational journal of molecular sciences · 2025Article
- Diagnosing Sepsis Through Proteomic Insights: Findings from a Prospective ICU Cohort.medRxiv : the preprint server for health sciences · 2025Article
- From cardiac injury to omics signatures: a narrative review on biomarkers in septic cardiomyopathy.Clinical and experimental medicine · 2025Review
- Interferon-Stimulated Genes and Immune Metabolites as Broad-Spectrum Biomarkers for Viral Infections.Viruses · 2025Review
- Biomarkers for primary graft dysfunction after lung transplantation: a review of current evidence and future prospects.Frontiers in physiology · 2025Review
- PreBP: an interpretable, optimized ensemble framework using routine complete blood count for rapid pathogen identification in bacterial pneumonia.Frontiers in bioinformatics · 2025Article
- Harnessing the host response for precision infectious disease diagnosis.Clinical microbiology reviews · 2024Review
- Adrenomedullin as a New Prosperous Biomarker in Infections: Current and Future Perspectives.Journal of clinical medicine · 2024Review
- Early Fever in Allogeneic Stem Cell Transplantation: Are Presepsin and YKL-40 Valuable Diagnostic Tools?Journal of clinical medicine · 2024Article
- The Pivotal Role of Presepsin in Assessing Sepsis-Induced Cholestasis.Diagnostics (Basel, Switzerland) · 2024Article
- Navigating the Modern Landscape of Sepsis: Advances in Diagnosis and Treatment.International journal of molecular sciences · 2024Review
- Article
- PAMPs and DAMPs in Sepsis: A Review of Their Molecular Features and Potential Clinical Implications.International journal of molecular sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe early diagnosis of sepsis is hampered by the lack of reliable laboratory measures. There is growing evidence that presepsin and Mid-regional pro-adrenomedullin (MR-proADM) are promising biomarkers in the diagnosis of sepsis. This study was conducted to evaluate and compare the diagnostic value of MR-proADM and presepsin in sepsis patients.
methodsWe searched Web of Science, PubMed, Embase, China national knowledge infrastructure, and Wanfang up to 22th July, 2022, for studies evaluating the diagnosis performance of presepsin and MR-proADM in adult sepsis patients. Risk of bias was assessed using quadas-2. Pooled sensitivity and specificity were calculated using bivariate meta-analysis. Meta-regression and subgroup analysis were used to find source of heterogeneity.
resultsA total of 40 studies were eventually selected for inclusion in this meta-analysis, including 33 for presepsin and seven for MR-proADM. Presepsin had a sensitivity of 0.86 (0.82-0.90), a specificity of 0.79 (0.71-0.85), and an AUC of 0.90 (0.87-0.92). The sensitivity of MR-proADM was 0.84 (0.78-0.88), specificity was 0.86 (0.79-0.91), and AUC was 0.91 (0.88-0.93). The profile of control group, population, and standard reference may be potential sources of heterogeneity.
conclusionsThis meta-analysis demonstrated that presepsin and MR-proADM exhibited high accuracy (AUC ≥ 0.90) in the diagnosis of sepsis in adults, with MR-proADM showing significantly higher accuracy than presepsin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.